CIM20EAPP3-01-47 is a late-maturing, high-yielding, white maize hybrid, with resistance to GLS, TLB, rust, and ear rots, bred for target agroecologies of the highlands of eastern Africa. |
|
General Information |
|
Region |
Eastern Africa |
|
Adaptation/Agroecological zone |
1800-2400 masl |
|
Type of product |
Three-way cross |
|
Year first announced |
2022 |
|
|
|
|
|
Grain Yield |
|
Kernel Characteristics |
Grain yield (opt.) |
9.22 t/ha |
|
Kernel color |
White |
Grain yield under on-farm conditions |
9.3 t/ha |
|
Kernel texture |
Semi-dent |
Grain yield under low N stress |
2.81 t/ha |
|
|
|
Grain yield (RS) |
5.75 t/ha |
|
Biotic Stress Performance |
|
|
|
Grey leaf spot (GLS) (AI) (1-9) |
3.6 |
Agronomic Characteristics |
|
Turcicum leaf blight (TLB) (AI) (1-9) |
3.7 |
50% anthesis |
772.9 GDD |
|
Rust (nat.) (1-9) |
3.5 |
Anthesis-silking interval |
2 days |
|
Ear rots |
3.5% |
Ear height |
113.1 cm |
|
Diseases are scored on a 1-9 scale, where 1 = Highly resistant; 5 = Tolerant; 9 = Highly susceptible. |
Plant height |
222.2 cm |
|
Ears per plant |
1.4 |
|
|
|
Bad husk cover |
4.3% |
|
Seed Production Characteristics |
Ear aspect (1-5) |
2.4 |
|
SC female parent yield |
11.3 t/ha |
Plant aspect |
2.8 |
|
Male parent yield |
3.7 t/ha |
Root lodging |
1.5% |
|
Nicking |
-5.4 days |
Stalk lodging |
2.2% |
|
|
|
Plant and ear aspects are scored on 1-5 scale, where 1 = desirable and 5 = undesirable characteristics |
|
Comments |
|
Product information is based on data from the CIMMYT East Africa 2020 Regional Trial (CIM20EAPP3) and 2021 regional on-farm trials (EA-ROFT 2021-1A). Actual performance will vary depending on a number of agronomic and environmental factors.
Abbreviations:
AI = artificial infestation/inoculation
GDD = growing degree-days (°C)
GLS = Grey Leaf Spot
Low N = managed low nitrogen stress
masl = meters above sea level
nat. = natural infestation
opt. = optimum (44,444 plants per ha)
RS = random stress
SC = single-cross
TLB = Turcicum Leaf Blight |
|
|
|
Further Links |
|
Full Product Announcement
(including trial results summary and site information) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|